BioMarin will no longer continue developing Kyndrisa after reports of negative reviews by the European Medicines Agency surfaced. The biotech company, however, will pursue next generation antisense oligonucleotides research.
BioMarin To Halt Development Of $680M Duchenne Muscular Dystrophy Drug
Tech Times - 1 Jun 2016 14:34
BioMarin will no longer continue developing Kyndrisa after reports of negative reviews by the European Medicines Agency surfaced. The biotech company, however, will pursue next generation antisense oligonucleotides research.
Share this Article
Recommended